TrialSignal
Clinical trial intelligence report
A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01137786
Status
COMPLETED
Phase
PHASE4
Sponsor
Bracco Diagnostics, Inc
Executive brief
Investment-Ready Snapshot
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01137786
Indication
Coronary Artery Stenosis
Modality
small molecule
Target
Non ionic contrast media comparator, Non ionic contrast media comparator
Intervention
Non ionic contrast media comparator, Non ionic contrast media comparator
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.